Asset overview
The Sapogenins
We continue to progress our strategy of focussing on our pharmaceutical programmes, specifically on the development of Cogane™ for Parkinson’s disease, and headline results from the CONFIDENT-PD clinical trial are expected in February 2013.
|
|
Programme |
2012 Key highlights |
|
|
Cogane™ |
Parkinson’s disease |
CONFIDENT-PD: April 2012 – completion of recruitment |
CONFIDENT-PD: Early December 2012 – last patient completed |
|
A Phase I bioavailability clinical trial of new solid dose oral formulations initiated |
|||
|
ALS |
Positive data from preclinical evaluation |
Charitable funding opportunities being evaluated |
|
|
Myogane™ |
Glaucoma |
Inconclusive results in a preclinical model which prevented evaluation of a neuroprotective action |
|
|
P61 |
Inflammatory diseases |
Characterisation of lead compound ongoing |
|